Skip to main
BDX
BDX logo

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 29%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson's positive outlook is supported by robust sales growth, with the Medical Surgical Systems (MMS) segment reporting $888 million in FQ3'25, reflecting a year-over-year increase of 5.3%, driven by strong demand in Infusion Systems and growth in Dispensing Solutions and Pharmacy Automation. The company's MedTech business has consistently achieved annual growth rates exceeding 6% since the launch of its BD 2025 initiative, coupled with improving margins, indicating strong operational efficiency and market positioning. Additionally, the Medical Device Solutions (MDS) segment demonstrated solid performance, with FY24 sales reaching $4.43 billion, representing a 3.2% increase year-over-year, further reinforcing the company's strong financial foundation in the healthcare sector.

Bears say

Becton Dickinson's organic revenue growth outlook has been downgraded from 4.0-4.5% to 3.0-3.5%, indicating a decline in expected sales performance. In FQ3'25, the company reported $1.25 billion in sales, a decrease of 1.1% year-over-year, attributed to low-single digit declines in the Biosciences and Diagnostic Solutions segments, along with stagnation in Specimen Management. Additional challenges include volume-based procurement headwinds in China and reduced demand in the Biosciences sector due to government cuts to research grants, which collectively exert pressure on revenue growth.

BDX has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 7 analysts, BDX has a Buy consensus rating as of Dec 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.